Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
about
Atypical antipsychotics for people with both schizophrenia and depressionAtypicality of atypical antipsychotics.Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewPublication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration databaseExtrapyramidal side-effects of antipsychotics in a randomised trial.Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.Ziprasidone for schizophrenia and severe mental illness.Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic ReviewAn Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia.The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.Ziprasidone-associated mania: a case series and review of the mechanism.Ziprasidone, a new atypical antipsychotic drug.Ziprasidone hydrocloride: what role in the management of schizophrenia?Placebo response in antipsychotic clinical trials: a meta-analysis.Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trialThe "delayed onset" of antipsychotic action--an idea whose time has come and gone.Antipsychotic medication: effects on regulation of glucose and lipids.Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trialZiprasidone: the fifth atypical antipsychotic.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers.How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia.Antipsychotics and QT prolongation.Atypical antipsychotics and mood stabilization in bipolar disorder.Atypical antipsychotics in the treatment of bipolar disorder.Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label studyOptimizing dosing in atypical neuroleptic monotherapyClinical pharmacology of atypical antipsychotics: an update.Atypical antipsychotics: newer options for mania and maintenance therapy.Higher than Physician's Desk Reference (US) doses on atypical antipsychotics.Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.The role of quetiapine in the treatment of bipolar disorder.The metabolic effects of antipsychotic medications.Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
P2860
Q24242037-8A310602-50B0-44D5-9E45-A0B11A9346D0Q24535908-72190E6F-0D68-448E-9AF3-10D558A17173Q28079821-992720C2-DCE0-4148-BF56-3E5A6838E05BQ28481584-B576A75A-195B-432F-BADD-4348B983695CQ30492645-E844C908-29F0-42D2-9E3E-B817464A7E93Q30501297-5F8ECA56-9DCE-4D83-B6E1-CB56C3171973Q30667146-C199C4E0-F76C-439D-8AA2-9174BD26D1EFQ30868078-C446DA2E-54E6-42A5-ABA2-299D23CDF558Q30984472-4BCFD4FD-B1F6-4BCB-800E-713CA196E999Q33223628-1DDE7E02-9629-4A52-9A4E-AC9DBE4B7AC6Q33695789-F337637D-7000-4FFB-B506-68F08E6E4D92Q33715077-629D93FF-047B-4E55-A55B-B2277A3F4E32Q33845251-A872AA6F-6205-4FB9-9B5C-F658E547BB6EQ34106516-4CC7A7EA-2775-49E6-A6FD-34AAA18C7E60Q34186039-17C11E41-54F3-40B3-BD0E-FFDD7EB8EC6EQ34278844-7CDDB30E-608E-4BE0-BB96-070A6D8A5ACDQ34357931-E560EC6D-4488-4FB1-8E47-AD42E23208C5Q34443837-CC239AF0-3971-4925-B469-2607654D18CFQ34480263-C185CF1C-BDE6-4BBB-95D7-2B6BB8D55357Q34480502-0FD24903-1E55-4D51-8CF3-D03AFE07771AQ34515378-A0CDDDB3-6618-4DC4-AA60-BF08921AA297Q34544566-E23FC8EB-E803-4FE4-940A-FDBFEEC379D2Q34604314-65F7ABD3-680E-4F27-A0AA-699E671DE23FQ34615595-9CB25AA9-05BB-4DFB-AD1C-A61115884B9AQ34640811-3CFB13D5-4018-4FDA-8327-4AD9F675EC51Q34665858-7C7EE8B7-D4D9-4100-8B39-FFF779566249Q34733976-E68F13FF-EC23-4544-BCE0-07FBC4E8B409Q34879022-70551FB1-4A2F-4146-A347-C539B91E22A4Q35048069-A07D8CFD-5FEB-4280-97CD-506F75B8A595Q35073763-09C4CF53-2AAA-4EEC-9158-E8292048A102Q35124712-62D46FDE-3DBE-49D1-B6CB-32CAECFED7E1Q35191252-E628ADC7-53C5-4F77-9641-17AFBE027034Q35236514-0A8666A1-44A7-41ED-90EC-D82787D5D4F8Q35728228-0417EEFE-A1CF-4270-A4C6-B076D7E8A2EDQ36158824-27F12C2D-4CF8-4738-9B79-85F6EBC351C2Q36191013-F7D8CF72-A54C-4F5E-8667-17C50A9B8131Q36346334-DFD497A3-824F-4E78-A332-55314B083796Q36458469-568F1D64-948A-48A9-BA34-ECCA35D77E90Q36577856-CC5E336F-D289-4D35-B8EA-5A7F00D23B48Q36626242-2F9A7D6F-3D90-4E93-AFC3-F4747E846226
P2860
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Ziprasidone 80 mg/day and 160 ...... rial. Ziprasidone Study Group.
@ast
Ziprasidone 80 mg/day and 160 ...... rial. Ziprasidone Study Group.
@en
type
label
Ziprasidone 80 mg/day and 160 ...... rial. Ziprasidone Study Group.
@ast
Ziprasidone 80 mg/day and 160 ...... rial. Ziprasidone Study Group.
@en
prefLabel
Ziprasidone 80 mg/day and 160 ...... rial. Ziprasidone Study Group.
@ast
Ziprasidone 80 mg/day and 160 ...... rial. Ziprasidone Study Group.
@en
P2093
P1476
Ziprasidone 80 mg/day and 160 ...... rial. Ziprasidone Study Group.
@en
P2093
D G Daniel
D L Zimbroff
E P Harrigan
K R Reeves
M Lakshminarayanan
P304
P356
10.1016/S0893-133X(98)00090-6
P407
P577
1999-05-01T00:00:00Z
P6179
1052038056